Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair Munro, Nick Andrews, Parvinder K. Aley et al.|The Lancet Infectious Diseases|2022Cited by 180
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) VaccineMerryn Voysey, Alastair McGregor, Sue Ann Costa Clemens et al.|SSRN Electronic Journal|2021Cited by 31